See the original post:
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh